|
[1]BOONSTRA K,BEUERS U,PONSIOEN CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review[J].J Hepatol,2012,56(5):1181-1188.
|
|
[2]ARNDTZ K,HIRSCHFIELD GM.The pathogenesis of autoimmune liver disease[J].Dig Dis,2016,34(4):327-333.
|
|
[3]ZHANG LN,SHI TY,SHI XH,et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis:results of a 14-year cohort study[J].Hepatology,2013,58(1):264-272.
|
|
[4]LAMMERT C,JURAN BD,SCHLICHT E,et al.Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients[J].J Gastroenterol,2014,49(10):1414-1420.
|
|
[5]RUDIC JS,POROPAT G,KRSTIC MN,et al.Ursodeoxycholic acid for primary biliary cirrhosis[J].Cochrane Database Syst Rev,2012,12:CD000551.
|
|
[6]TRIVEDI PJ,LAMMERS WJ,van BUUREN HR,et al.Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis:a multicentre international study[J].Gut,2016,65(2):321-329.
|
|
[7]ANGULO P,JORGENSEN RA,KEACH JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology,2000,31(2):318-323.
|
|
[8]LEVY C.Targeting the farnesoid x receptor in patients with cholestatic liver disease[J].Gastroenterol Hepatol(N Y),2016,12(4):263-265.
|
|
[9]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.
|
|
[10]SHIPMAN KE,STRANGE RC,RAMACHANDRAN S.Use of fibrates in the metabolic syndrome:a review[J].World J Diabetes,2016,7(5):74-88.
|
|
[11]Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性肝汁性肝硬化(又名原发性胆汁性胆合炎)诊断和治疗共识[J].临床肝胆病杂志.2015,31(12):1980-1988.
|
|
[12]DOHMEN K,WEN CY,NAGAOKA S,et al.Fenofibrate-induced liver injury[J].World J Gastroenterol,2005,11(48):7702-7703.
|
|
[13]TSIMIHODIMOS V,MILTIADOUS G,BAIRAKTARI E,et al.Possible mechanisms of the fibrate-induced increase in serum creatinine[J].Clin Nephrol,2002,57(5):407-408.
|
|
[14]IWASAKI S,TSUDA K,UETA H,et al.Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis[J].Hepatol Res,1999,16(1):12-18.
|
|
[15]HAN XF,WANG QX,LIU Y,et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis,2012,13(4):219-224.
|
|
[16]LENS S,LEOZ M,NAZAL L,et al.Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid[J].Liver Int,2014,34(2):197-203.
|
|
[17]HOSONUMA K,SATO K,YAMAZAKI Y,et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol,2015,110(3):423-431.
|
|
[18]CHEUNG AC,LAPOINTE-SHAW L,KOWGIER M,et al.Combined ursodeoxycholic acid(UDCA)and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J].Aliment Pharmacol Ther,2016,43(2):283-293.
|
|
[19]OHMOTO K,YOSHIOKA N,YAMAMOTO S.Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis[J].J Gastroenterol,2006,41(5):502-503.
|
|
[20]ZHANG Y,CHEN K,DAI W,et al.Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis:a meta-analysis[J].Hepatol Res,2015,45(1):48-58.
|
|
[21]ZHANG Y,LI S,HE L,et al.Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis[J].Drug Des Devel Ther,2015,9:2757-2766.
|
|
[22]KUIPER EM,HANSEN BE,de VRIES RA,et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J].Gastroenterology,2009,136(4):1281-1287.
|
|
[23]HEGADE VS,KHANNA A,WALKER LJ,et al.Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score[J].Dig Dis Sci,2016,61(10):3037-3044.
|
|
[24]LEVY C,PETER JA,NELSON DR,et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Aliment Pharmacol Ther,2011,33(2):235-242.
|
|
[25]CUPERUS FJ,HALILBASIC E,TRAUNER M.Fibrate treatment for primary biliary cirrhosis[J].Curr Opin Gastroenterol,2014,30(3):279-286.
|
|
[26]KLUTH M,STINDT J,DROGE C,et al.A mutation within the extended X loop abolished substrate-induced ATPase activity of the human liver ATP-binding cassette(ABC)transporter MDR3[J].J Biol Chem,2015,290(8):4896-4907.
|
|
[27]GHONEM NS,ANANTHANARAYANAN M,SOROKA CJ,et al.Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion[J].Hepatology,2014,59(3):1030-1042.
|
|
[28]NAKAMUTA M,FUJINO T,YADA R,et al.Therapeutic effect of bezafibrate against biliary damage:a study of phospholipid secretion via the PPARalpha-MDR3 pathway[J].Int J Clin Pharmacol Ther,2010,48(1):22-28.
|
|
[29]HONDA A,IKEGAMI T,NAKAMUTA M,et al.Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J].Hepatology,2013,57(5):1931-1941.
|
|
[30]THOMAS M,BURK O,KLUMPP B,et al.Direct transcriptional regulation of human hepatic cytochrome P450 3A4(CYP3A4)by peroxisome proliferator-activated receptor alpha(PPARalpha)[J].Mol Pharmacol,2013,83(3):709-718.
|
|
[31]GHONEM NS,ASSIS DN,BOYER JL.Fibrates and cholestasis[J].Hepatology,2015,62(2):635-643.
|
|
[32]LI F,PATTERSON AD,KRAUSZ KW,et al.Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis[J].J Lipid Res,2012,53(8):1625-1635.
|
|
[33]MARX N,SUKHOVA GK,COLLINS T,et al.PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1expression in human endothelial cells[J].Circulation,1999,99(24):3125-3131.
|
|
[34]GALLI A,CRABB DW,CENI E,et al.Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro[J].Gastroenterology,2002,122(7):1924-1940.
|
|
[35]XIE C,LI L,XU YP,et al.Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis[J].Chin J Hepatol,2013,21(12):914-919.(in Chinese)谢聪,李龙,许雅苹,等.非诺贝特的抗小鼠肝纤维化作用[J].中华肝脏病杂志,2013,21(12):914-919.
|
DownLoad: